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The photoreceptor phosphodiesterase (PDE6) regulates the
intracellular levels of the second messenger cGMP in the outer
segments of cone and rod photoreceptor cells. PDE6 contains
two regulatory GAF domains, of which one (GAF A) binds
cGMP and regulates the activity of the PDE6 holoenzyme. To
increase our understanding of this allosteric regulation mecha-
nism, we present the 2.6 A˚ crystal structure of the cGMP-bound
GAF A domain of chicken cone PDE6. Nucleotide specificity
appears to be provided in part by the orientation of Asn-116,
which makes two hydrogen bonds to the guanine ring of cGMP
but is not strictly conserved among PDE6 isoforms. The isolated
PDE6C GAF A domain is monomeric and does not contain suf-
ficient structural determinants to formahomodimer as found in
full-length PDE6C. A highly conserved surface patch on GAF A
indicates a potential binding site for the inhibitory subunit P.
NMRstudies reveal that the apo-PDE6CGAFAdomain is struc-
tured but adopts a significantly altered structural state indicat-
ing a large conformational change with rearrangement of sec-
ondary structure elements upon cGMP binding. The presented
crystal structure will help to define the cGMP-dependent regu-
lation mechanism of the PDE6 holoenzyme and its inhibition
through P binding.
Light detection by rod and cone photoreceptors of vertebrate
retina is a complex signal transduction process that utilizes
cGMP as an intracellular messenger in the conversion of pho-
ton stimulation into an electrical response. Upon light stimula-
tion, the phototransduction cascade begins with activation of
light-sensitive rhodopsin, which activates the G-protein trans-
ducin, whose G subunit binds and sequesters an inhibitory
subunit P of the photoreceptor phosphodiesterase (PDE6).4
This in turn leads to the activation of the catalytic subunit of
PDE6 and hydrolysis of cGMP (1, 2). By lowering the intracel-
lular cGMP levels, activated PDE6 causes hyperpolarization of
the photoreceptor cell via cGMP-gated ion channels. cGMP
levels are quickly restored by synthesis through calcium-sensi-
tive photoreceptor guanylyl cyclases to re-establish the dark-
adapted state. As a rapid turnover of cGMP is mandatory for
effective visual function, PDE6 is well adapted for this purpose.
Rod photoreceptors are at least a hundred times more sensi-
tive to light than cone photoreceptors. Nevertheless, cone pho-
toreceptors are able to respondmore quickly and terminate the
light signalmore rapidly (3). Structural differences between rod
and cone isoforms of PDE6 are thought to be critical determi-
nants of the photoreceptor responses as they display subunit
organizations that differ between rod and cone isoforms. Rod
PDE6 contains two distinct catalytic subunits ( and) and two
inhibitory P subunits to form a heterotetramer (P2),
whereas cone PDE6 contains two identical cone-specific cata-
lytic subunits  and two cone-specific P subunits to form
P22 (4). Most previous biochemical studies have utilized the
heteromeric P2 holoenzyme from rod photoreceptors. Less
is known about the cone photoreceptor isoform of PDE6.
PDE6 is one of 11 vertebrate cyclic nucleotide PDE families.
Of these, PDE2, -5, -6, -10, and -11 contain tandem GAF
domains (GAF A and GAF B) that are located N-terminally to
the more conserved catalytic domains. The acronym GAF is
derived from the first identified GAF domain-containing pro-
tein families: mammalian cGMP-regulated PDEs, Anabaena
adenylyl cyclases, and the Escherichia coli transcription factor
FhlA (5). GAF domains are small molecule binding domains
that are structurally related to Per-ARNT-Sim domains (6, 7).
GAF domains are conserved over more than 3 billion years and
function as signal transduction modules in light detection of
plants (8), sodium sensing (9), and may in some cases even
display enzymatic activity (10).
At this point, the details of the regulatory mechanism(s) and
the exact roles of the GAF A and GAF B domains of PDE6
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remain elusive. GAF A from PDE6C has been shown to bind
cGMP (11), but whether cGMP binding activates the catalytic
domain through an allosteric conformational change as
reported for PDE2A and PDE5A (12, 13) remains to be deter-
mined. Binding of cGMP to rod PDE6 has been shown to
increase the binding affinity of P to the holoenzyme (14, 15).
Cross-linking studies of rod P to the catalytic PDE6 -het-
erodimer revealed that P binds in an extended manner, with
the N-terminal, polycationic region binding in the vicinity of
GAFA, and theC-terminal region in the vicinity of the catalytic
domain (16) as confirmed by NMR (17). P binding blocks cat-
alytic activity and also increases the affinity of GAF A for
cGMP. As no recombinant PDE6 holoenzyme has been suc-
cessfully expressed, we have utilized the recombinantly
expressed GAF A domain of chicken PDE6C in an attempt to
gain insights into the structural nature and function of the allo-
steric cGMP-binding site and of the oligomerization of the
PDE6 holoenzyme.
In this study, we report a 2.6 Å crystal structure of the GAFA
domain from chicken cone PDE6. Although the overall fold is
similar to other knownGAF domains, a detailed comparison of
the cGMP-binding pockets of PDE6C GAF A and PDE2A GAF
B reveals significant differences, indicating that the PDE GAF
domains have a variety of ways to bind the identical ligand, an
observation that is consistentwith their widespread occurrence
as ligand-binding domains in signal transduction pathways (5,
18). The monomeric structure of GAF A stands in contrast to
the dimeric crystal structure of PDE2AGAF AB, in which GAF
A is part of the dimerization interface of a parallel dimer (19).
Furthermore, combined NMR and circular dichroism studies
reveal that the ligand-free form of PDE6CGAFA adopts a ther-
modynamically less stable structural state that is significantly
altered compared with the cGMP-bound state.
EXPERIMENTAL PROCEDURES
Cloning, Expression, and Purification—cDNA for full-length
chicken PDE6C was a generous gift from Dr. Susan Semple-
Rowland (University of Florida). GAF A (residues 55–225 plus
the C-terminal LE(H6) tag) was expressed in C41 E. coli cells (a
derivative strain of BL21(DE3) (20)) and grown in LB media or
M9minimalmedia plus Se-Met for Se-Met-labeled protein (21)
at 37 °C and 200 rpm to an A600 of 0.5–0.6, at which point
isopropyl 1-thio--D-galactopyranoside to a final concentra-
tion of 0.2 mM was added, and the temperature was lowered to
16 °C for 18–24 h.
Purification was performed at 4 °C. Four buffers were pre-
pared: lysis (50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 5 mM imid-
azole, 20% glycerol, 1 mM phenylmethylsulfonyl fluoride);
wash-1 (50 mM Tris-HCl, pH 8.0, 15 mM imidazole, 20% glyc-
erol, 400 mM NaCl, 2 mMMgCl2); wash-2 (same as wash-1, but
10 mM NaCl); and elution (50 mM Tris-HCl, pH 8.0, 250 mM
imidazole, 20% glycerol, 10 mMNaCl, 2 mMMgCl2). After cen-
trifugation at 3,000  g, cells were resuspended in lysis buffer
and lysed in a microfluidizer at 10,000 p.s.i. After centrifuga-
tion, the lysate was applied to a nickel-nitrilotriacetic acid grav-
ity column (15 ml). The column was washed with wash-1 and
wash-2 buffers. Protein was eluted with elution buffer and then
applied to 25 ml of epoxy-Sepharose cGMP affinity resin (col-
umn size of 25 mm) and washed with high salt buffer (0.5 M
NaCl, 20mMTris-HCl, pH 7.5, 0.1mM EDTA, 1mM -mercap-
toethanol) and low salt buffer (same as high salt buffer but with
0.2 M NaCl). The protein was eluted with low salt buffer (plus 1
mM cGMP (Sigma)). Usual yields of purified protein were 5
mg from 9 liters of LB culture. The protein was determined to
be95% pure by SDS-PAGE.
Crystallization, Structure Determination, and Refinement—
The purified GAF A domain was concentrated in Centricon 30
units (Millipore) to 5 mg/ml and exchanged into 20 mM Tris-
HCl, pH 7.5, 20 mM NaCl, 0.1 mM EDTA, 1 mM -mercapto-
ethanol, 1 mM cGMP. Crystals were grown at room tempera-
ture in sitting drops with 0.5 ml of precipitant (1.5–1.8 M
ammonium sulfate, 0.1 M sodium acetate, pH 4.5–5.0) in the
reservoir and equal volumes (2–10 l) of protein and precipi-
tant in the drop. Crystals grew to maximum dimensions of
600  300  250 m within several weeks and were then
frozen in liquid nitrogen after soaking for 2–3 min in cryo-
buffer (20% v/v glycerol, 1.5 or 1.6 M ammonium sulfate, 100
mM sodium acetate, pH 4.5 or 5.0, 1 mM cGMP, 1 mM -mer-
captoethanol, 0.1 mM EDTA). A 2.5 Å SAD peak Se-Met data
set was collected from a crystal in cryo-buffer (pH 5.0, 1.6 M
ammonium sulfate) at 12,662.5 eV (0.97912 Å) (1 eV 1.602
1019 J) at the National Synchrotron Light Source beamline
X4A. Nine of the 10 selenium atoms (five seleniums for each of
two monomers in asymmetric unit) were determined with the
program SOLVE (22). Two sets of four selenium positions each
were found related in the density by non-point group symmetry
and used for averaging and solvent flattening in a 3.0 Å
RESOLVE map (23). A model was built manually using the
COOT program (24) and refined using a 2.6 Å native sulfome-
thionine data set collected from a crystal in cryo-buffer (pH 4.5,
1.5 M ammonium sulfate) with the program CNS, using
restrained individual B factors (25). Further refinement was
performed in REFMAC using TLS refinement and riding
hydrogens (26). The final model consists of residues 55–225
with an Rfree factor of 25.7% and Rwork factor of 22.1%. The
space group was P3221, and 87.6% of the residues in the final
model were in the most favored area of the Ramachandran plot
(additional structural statistics are provided in supplemental
Table S1). The atomic coordinates are deposited in the Protein
Data Bank (code 3dba).
Preparation of Isotopically Labeled PDE6 GAF A and NMR
Experiments—Uniformly 15N-labeled PDE6C GAF A for NMR
studies was grown in M9 minimal media with 15N-NH4Cl
(Cambridge Isotope Laboratories). Cell lysis and nickel affinity
column chromatography were carried out as described above.
The nickel column eluate was concentrated and injected onto a
Superdex 75 column. A single peak was eluted with 150 mM
NaCl, 25 mM sodium phosphate, pH 7.0, 0.1 mM EDTA. Upon
fractionation, dithiothreitol to a final concentration of 1 mM
was added. NMR samples were concentrated to 150 M,
and 10% D2O was added. cGMP to a final concentration of 1
mM was added for the spectrum of the cGMP-bound form.
1H,15N HSQC spectra were collected at 20 °C on a Varian
800-MHz INOVA spectrometer equipped with 1H-13C,15N-
cold probe. All spectra were processed and analyzed using
NMRDraw (27) and NMRView (28).
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Determination of the Rotational Correlation Time—To
determine the rotational correlation time of 0.7 mM PDE6C
GAF A in the presence of cGMP, we measured 15N spin relax-
ation parameters (R1, R2) and the steady-state heteronuclear
1H,15NNOEs using standard pulse sequences (29) at 37 °C on a
Bruker 500 MHz DMX spectrometer. 15N-T1 relaxation delays
were 10, 50, 100, 200, 400, 600, 800, and 1000 ms (underlined
delays were duplicated). 15N-T2 relaxation delays were 17.2,
34.4, 51.7, 69.0, 86.2, 103.5, and 120.7 ms (underlined delays
were duplicated). Only well resolved resonances were used for
the dynamics analysis (85 resonances) by NMRView (28) and
Modelfree 4.15 (30).
Circular Dichroism Studies—Circular dichroism studies
were performed on a 62A DS spectrometer (Aviv Biomedical).
Spectra were collected with 10–20 M PDE6C GAF A in 100
mMNaCl, 25mM sodiumphosphate, pH 7.0, 0.1mMdithiothre-
itol in the absence and presence of 0.5 mM cGMP (cuvette path
length, 0.1 cm). To monitor the temperature-dependent dena-
turation through thermal scans, ellipticity at the-helical signal
of 222 nm as a function of temperature was measured in the
range of 10–85 °Cwith steps every 3 °C and a 60-s equilibration
time at each step.
RESULTS
Overall GAF Domain Fold—The crystal structure of the
chicken PDE6C GAF A domain, determined at a resolution of
2.6 Å, displays a typical GAF domain fold with a six-stranded
antiparallel -sheet arranged in the strand order 3-2-1-6-5-4
(Fig. 1A). The-sheet provides the floor, and the two helices3
and 4 comprise the roof of a deeply buried cGMP-binding
pocket. The helical dipole of 3, which is between 3 and 4 in
the primary structure, points toward the phosphate group of
the bound cGMPmolecule. 4, which is between 4 and 5 in
sequence, sits atop the cGMPmolecule. Helices 1 and 2 pre-
cede the first-strand and, together with5, form a three-helix
bundle that packs against the-sheet on the opposite side of the
cGMP-binding pocket. Strands 2 and 3 are connected by an
18-residue loop that includes a short -helix (2/3). Excluding
helix 1, both monomers in the asymmetric unit superimpose
well with a root mean square deviation of 0.5 Å over 149 equiv-
alent C- atoms.
The crystal structure of chicken PDE6C GAF A indicates that
GAF A does not form a homodimer. The asymmetric unit of the
crystal contains two monomers that do not dimerize with each
other or with monomers related by lattice symmetry. Notably,
helix1 is in a different orientation in the twomonomers (Fig. 1A)
because of a distinct packing environment of each monomer and
lack of a dimerization interface to restrain the helix. To confirm
the monomeric state in solution, we determined the rotational
correlation time c of cGMP-bound 15N-PDE6C GAF A through
15N relaxationmeasurements byNMR.The calculated value for c
of 12.4 ns at 37 °C is in a range typical for proteins of similar size
(20 kDa), therefore confirming that GAF A is monomeric in
solution at millimolar concentrations. Apo and cGMP-bound
PDE6CGAFAelute at the sameelutionvolumeandhave identical
elution peak shape in analytical size exclusion chromatograms
(supplemental Fig. S1). Together, the data indicate that GAF A is
intrinsically amonomer and that cGMPbinding does not alter the
oligomeric state of GAF A.
cGMP-binding Site of PDE6C GAF A—Cyclic GMP is bound
in the anti-conformation (Fig. 1B), similar to cGMP in PDE2A
GAF B (19) and cAMP in the tandem GAF domains of the cya-
nobacterial adenylyl cyclase cyaB2 (31) and PDE10A GAF B (32).
Similar to the previously solved cyclic nucleotide-binding GAF
domains, nearly the entire 493 Å2 of solvent-accessible surface
area of the nucleotide is buried in PDE6C, indicating that theGAF
domain is in a closed state that forms upon cGMP binding.
Because of a lower overallB factor, we use chainA to describe
the binding pocket. The electron density map shows that the
3,5-cyclic phosphate group is in the chair conformation (sup-
plemental Fig. S2). The N-terminal end of helix 3 points
FIGURE 1. A, overall structure of PDE6C GAF A. Ribbon diagram of chain A. Secondary structure elements are labeled.-Helices are shown in cyan;-strands in
purple, and loops in tan. cGMP is shown as red sticks. Chain B was superimposed (residues 92–225) on chain A, and the first two helices (residues 55–91) from
chain B are shown in green. This figure was generated with PyMOL (DeLano Scientific). B, cGMP-binding site of chicken PDE6C GAF A. The backbone is shown
as a ribbon and side chains contacting the cGMP as sticks. Shown are five side chain contacts (Ser-97, Asn-116, Asp-169, Thr-172, and Thr-176), four backbone
contacts (Asn-116, Ile-142, Ala-143, and Ser-165), five hydrophobic contacts (Phe-99, Leu-115, Tyr-174, Leu-168, and Leu-197), and three contacts with waters
(HOH-254, -257, and -264). Arg-95 andMet-195 donotmake contactswith cGMPbut are discussed in the text. This figurewas generatedwith CCP4MG (47, 48).
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toward the phosphate group, bringing the negatively charged
phosphate group adjacent to the partial positive charge of the
helix dipole. The guanine ring makes several contacts to the
protein and is well defined through a series of protein-ligand
interactions (Fig. 1B and supplemental Fig. S3). Asn-116 pro-
vides two important cGMP-specific protein-ligand hydrogen
bonds. The carbonyl oxygen of its side chain makes a 2.7-Å
hydrogen bond to the protonated N-1 of the guanine ring, and
its backbone amide makes a 2.9 Å hydrogen bond to the O-6
carbonyl oxygen of cGMP. Furthermore, Asn-116 is locked into
position by a 3.0-Å salt bridge between the partial negative
charge of its carbonyl oxygen and the guanidine group of Arg-
95. Finally, Asn-116 may provide yet another specificity deter-
minant through a water-mediated hydrogen bond to the N-2
amino group (via HOH-264). Another hydrogen bond to the
N-2 amino group of the guanine ring is provided by the side
chain of Thr-172, which is 3.4 Å away. This side chain also
provides two water-mediated hydrogen bonds (via HOH-254)
to the N-2 amino group and the N-3 ring nitrogen. Ser-97 pro-
vides an additional 2.7 Å hydrogen bond to N-7 of the guanine
ring of cGMP. In addition to the described protein-ligand
hydrogen bond network, hydrophobic interactions play an
important role in the definition of the cGMP-binding pocket
and nucleotide orientation. The guanine ring is sandwiched
between the side chains from Phe-99, Leu-115, Leu-168, Tyr-
174, and Leu-197.
Conformational Change upon Binding of cGMP—We are
able to purify and concentrate the recombinant PDE6C GAF A
domain in the absence of cGMP to millimolar concentrations
but have been unsuccessful in producing diffraction-quality
crystals. Therefore, we utilized two-dimensional NMR spec-
troscopy to investigate the nature of the conformational change
between the ligand-free and cGMP-bound forms. An overlay of
1H,15N HSQC spectra of 15N-labeled PDE6C GAF A in the
absence and presence of cGMP (Fig. 2A) reveals that PDE6C
GAF A is folded in both cases. However, the two states adopt
significantly different conformations, as an overwhelming
majority of the amide resonances is perturbed by more than
a line width. The resonances in the spectrum of apo-PDE6C
GAFA vary widely in their intensities, indicative of exchange
among multiple states, with a subset of peaks broadened
beyond detection.
Circular dichroism spectra of both states of PDE6C GAF A
are virtually indistinguishable and both have a strong signal for
-helical secondary structure, indicated by minima at 208 and
218 nm. The negligible difference in the spectra suggests that
the two states do not differ significantly in their secondary
structural element content. To assess protein stability, we
measured the ellipticity at the -helical signal of 222 nm as a
function of temperature (Fig. 2B). The observed 20 °C increase
in the melting temperature upon addition of cGMP indicates
considerable thermodynamic stabilization of PDE6C GAF A
through cGMP binding. This supports the hypothesis that both
states differ in their global tertiary structure rather than
through local unfolding of secondary structure elements. Nev-
ertheless, the conformational change does not lead to an overall
altered hydrodynamic behavior as analytical size exclusion
chromatography reveals no observable difference in peak posi-
tion or shape (supplemental Fig. S1).
Conserved Interaction Surface—An alignment of PDE6 GAF
A sequences from cone and rod photoreceptors reveals that
stretches of the sequences between 1 and 3, which encom-
pass 2, 2/3, and 3, are strongly conserved with a large num-
ber of strictly conserved residues (Fig. 3A). When plotted onto
the crystal structure of PDE6C GAF A, several of these con-
served residues form a contiguous solvent-accessible surface
FIGURE 2. A, 1H,15N HSQC spectral overlay of PDE6C GAF A in the absence (red) and presence (black) of cGMP. B, percent unfolded plotted as a function of
temperature in °C for PDE6C GAF A in the absence (red) and presence (black) of cGMP. Ellipticity at 222 nmwasmeasured, and values at 10 and 85 °C were set
arbitrarily as 0%unfolded and100%unfolded, respectively. Values of the average from three independent experiments are shown. Error bars indicate standard
deviation.
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patch on the PDE6C GAF A structure (Fig. 3B). This surface
patch contains several charged residues. Arg-102 and Arg-104
are surrounded byGlu-109, Asp-131, andGlu-133. Val-135 and
Pro-137 extend the surface toward another negatively charged
residue, Asp-139 (Fig. 3C, left panel). Ile-140, Gly-141, andHis-
163, which all have been previously proposed to be in the vicin-
ity of the P-binding site (33, 34), are also within the conserved
surface or in close proximity to it (highlighted in magenta in
Fig. 3C). An elongated surface with numerous negatively
charged and hydrophobic residues can be drawn fromAsp-131
to His-163 and may be responsible for the interaction with
the polycationic region of P. A second smaller conserved
surface patch is located on the opposite side of GAF A. It
contains several positively charged amino acids (Fig. 3C,
right panel) indicating that it is less likely to be the interac-
tion surface for P.
DISCUSSION
Comparison of Overall GAF Domain Fold—The overall fold
of the PDE6C GAF A domain is very similar to the topology of
previously characterized cyclic nucleotide-binding GAF
domains. The largest difference between the published GAF
domain structures is the length and sequence of the2-3 loop,
as was previously discussed (31). This stretch contains a short
helical turn in PDE6C, termed 2/3, which is positioned to
stabilize Asn-116, a critical cGMP-contacting residue. In par-
ticular, the side chains of Ser-121 and Asn-126 make hydrogen
bonds to the backbone carbonyl of Asn-116 and may help to
lock its side andmain chains into position to provide the nucle-
otide-selective hydrogen bonds. A solution structure of PDE5A
GAF A revealed that the cGMP-selective GAF domain of
PDE5A contains a similar helical turn (35).
Comparison of cGMP-binding Pockets of PDE6C and PDE2A—
Systematic alanine mutations of binding residues of PDE2A
GAF B revealed that three guanine-binding side chains (Asp-
439, Phe-438, and Thr-488) were required for the 30-fold
higher affinity for cGMP over cAMP (36). The side chain of
Asp-439 is hydrogen-bound to the guanine N-1, and its back-
bone amide is a hydrogen bonddonor to theO-6 carbonyl of the
guanine. Phe-438 is base-stacked with the guanine ring,
whereas Thr-488 contacts the guanine N-2 via a water-medi-
ated hydrogen bond. In PDE6C GAF A, these residues corre-
spond to Asn-116, Leu-115, and Thr-172.
Asn-116 of PDE6C, the equivalent residue to Asp-439 of
PDE2A, provides two protein-ligand hydrogen bonds (Fig. 1B)
and therefore serves as a negative determinant against cAMP
binding as both hydrogen bonds cannot be satisfied by the ade-
nine ring. Surprisingly, a sequence alignment of GAFA domain
sequences from PDE6A, -B, and -C of different species reveals
thatAsn-116 is variablewithin the PDE6 gene family and can be
an Asn, an Asp, or a Ser (Fig. 3A). As all three side chains have
oxygen atoms capable of serving as hydrogen bond acceptors, it
is likely that Ser, Asn, and Asp each make similar side chain
contacts to N-1 of the guanine ring. All other characterized
cGMP-binding GAF domains (PDE2A GAF B, PDE5A GAF A,
and PDE11A GAF A) have an Asp at the analogous position.
Leu-115 of PDE6C is equivalent to Phe-438 in PDE2A.
Whereas Phe-438 likely provides aromatic --base stacking
as it is aligned in parallel with the guanine ring, Leu-115 of
FIGURE 3.A, sequence alignment of PDE6A, -6B, and -6C fromdifferent species. The region between1 and3 is shown. Red, identical; orange, strongly similar;
yellow,weakly similar. Species are as follows: gg,Gallus gallus (chicken); us, Uta stansburiana (common side-blotched lizard); hs, Homo sapiens (human); pt, Pan
troglodytes (chimpanzee);mc, Macaca mulatto (rhesus monkey); ec, Equus caballus (Przewalski’s horse); bt Bos taurus (cattle); cf, Canis familiaris (dog);mm,
Mus musculus (mouse); rn, Rattus norvegicus (rat); rp, Rana pipiens (leopard frog); dr, Danio rerio (zebrafish); oa, Ornithorhynchus anatinus (platypus); pm,
Petromyzonmarinus (sea lamprey). The alignmentwas generatedwith ClustalW (49). The asterisk indicates the discussed residueAsn-116. Residueshighlighted
above alignment form a conserved surface patch and are shown as spheres inC. Sequence ofmouse PDE5A is shown for comparison. B, surface representation
of PDE6CGAFA.Colors arebasedon sequence conservationas inA. Discussed surfacepatch is indicatedbyblackdashed line.C, ribbon representationof PDE6C
GAF A. Side chain atoms of residues, which are part of the conserved surface in B, are shown as sphereswith nitrogen atoms in blue and oxygen atoms in red.
Residues thatwere previously implicated in Pbinding are highlightedwithmagenta-colored carbon atoms. cGMP is shown as stickswith green carbon atoms.
Crystal Structure of PDE6C GAF A
SEPTEMBER 19, 2008•VOLUME 283•NUMBER 38 JOURNAL OF BIOLOGICAL CHEMISTRY 25917
PDE6C provides hydrophobic interactions instead. The equiv-
alent amino acid in rod PDE6 (isoforms A and B) is a Phe,
whereas it is a Leu in most PDE6C sequences (Fig. 3A).
Thr-172 of PDE6Cmakes a direct hydrogen bond to the gua-
nineN-2, whereas Thr-488, the equivalent residue in PDE2A, is
too far for a direct hydrogen bond (3.8 Å) and makes a water-
mediated hydrogen bond instead. Other side chain contacts
with the cGMP molecule are similar in PDE6C and PDE2A.
Structural Determinants of Affinity and Specificity—GAF
domains from different PDEs bind cGMP and cAMP with a
wide variety of affinities and specificities. The tandem GAF
domains of PDE2A and PDE5A have low nanomolar affinities
for cGMP binding but vary in their selectivity against cAMP
from 30-fold (PDE2A (36)) to several thousandfold (PDE5A
(35, 37)). The tandemGAF domains from chicken PDE6C have
a similar high affinity for cGMP (KD of 10 nM) but discrimi-
nate over 3 million-fold against cAMP (KD of 35 mM) (38).
These binding constants imply that the cGMP selectivity of
PDE GAF domains is achieved largely by modulating the
strength of cAMP binding. The more selective a given PDE
GAF domain is, the weaker its affinity for cAMP.
As there are no structures available for the cAMP-bound
form of any cGMP-selective GAF domain, we can only infer
reasons for the lower cAMP affinities. The GAF domains of
PDE2A, PDE6C, and PDE5A all use a residue at the position
analogous to Asn-116 in PDE6C to make cGMP-specific con-
tacts. We propose that the difference in cAMP affinity (and
therefore, selectivity) between PDE6C and PDE2A stems from
the ability or inability of Asp-439/Asn-116 to swing out and
make room to accommodate cAMP. Consistent with this
hypothesis, the equivalent residue in the cAMP-binding
PDE10A GAF B is an Asp whose side chain points away from
the binding pocket allowing anArg tomake nucleotide-specific
contact with cAMP. As noted above, Asn-116 in PDE6C is
locked into position by its surrounding residues and helix 2/3.
In contrast, the shorter sequence between strands 2 and 3 in
PDE2A GAF B does not allow for formation of the 2/3 helix,
and there are no analogous contacts with Asp-439, thereby
allowing the residue to swing out and cAMP to bind more eas-
ily. PDE5A with its thousandfold cGMP preference also con-
tains a 2/3 helix in similar orientation (35).
cGMP-dependent Conformational Change—Todate, no high
resolution structure of a cyclic nucleotide-binding GAF
domain in the absence of its ligand has been reported. The
NMR spectra presented here provide evidence for a change
in both the conformation and flexibility of PDE6CGAFA upon
cGMP binding. Our data indicate that the apo-GAF A domain
adopts neither a preformed pocket nor an unstructuredmolten
globule formation but rather a dynamic domain with a struc-
tured core, suggesting the existence of two distinct states.
Recently, our laboratories investigated the cGMP-induced
conformational change of GAFA fromPDE5A (35). In contrast
to apo-GAF A of PDE6C, apo-GAF A of PDE5A is not stable in
solution. The presence of GAF B stabilizes GAF A of PDE5A
and enabled us to monitor the cGMP-dependent conforma-
tional change byNMR.Whereas apo-GAFAof PDE5A appears
to sample multiple dynamic states, which results in practically
no observed NMR resonances from GAF A, the core of apo-
GAF A from PDE6C is stably structured and therefore appears
to exist in a single state (Fig. 2A). This indicates that subtle
structuralanddynamicdifferencesinthemagnitudeofthecGMP-
dependent conformational changes between GAF domains
may exist. These may account for the large variety of cyclic
nucleotide affinities and different time scales of allosteric reg-
ulation. However, in both cases cGMP causes a large scale
induced fit of the GAF domain upon binding.
Dimerization—All PDEs are known to form dimers although
the functional significance of PDE dimerization remains elu-
sive. Themonomeric crystal structures of the catalytic domains
from PDE2A (39), PDE5A (40, 41), and PDE10A (42) imply that
the regulatory N-terminal region with tandem GAF domains
provide dimerization contacts. Our crystal structure reveals
that GAFA of PDE6C is not intrinsically dimeric, in contrast to
what EM studies suggest for the full-length PDE6AB enzyme
(43, 44). Although helix 1 is in approximately the same orien-
tation in chain A of our PDE6C GAF A crystal structure and
PDE2A GAF A (19) (supplemental Fig. S4), it is not involved in
a similar dimerization interface as indicated by the lack of crys-
tal packing contacts to restrain the conformation of the helix
(Fig. 1A) and the total correlation time of 12.4 ns in solution. A
previous report identified 1 as essential for affinity and selec-
tivity of heterodimerization in rod PDE6AB (45). The fact that
the presence of1 is not sufficient for homodimerization of our
cone PDE6C GAF A construct indicates that dimerization of
the full-length enzyme ismediated bymultiple regions and that
additional sequences directly N- and C-terminal to our recom-
binant GAF A construct (e.g. residues 1–54 or GAF B) are nec-
essary for dimerization of PDE6C. It is also likely that dimeriza-
tion contacts vary between the heterodimeric rod PDE6AB and
the homodimeric cone PDE6C. The diversity of dimerization
modes of the GAF-containing PDEs indicates that generaliza-
tions about the dimerization properties of individual GAF
domains cannot be made without high resolution structural
data from each PDE.
P-binding Site—Activity of the PDE6 holoenzyme is regu-
lated by the inhibitory P subunit, a small protein found in both
rod and cone photoreceptor cells. The recently determined
solution structure of bovine rod P revealed a loose fold with
transient structural features, characteristic of an intrinsically
disordered protein (17). P binds in an extendedmanner to rod
PDE6AB, and residues within the polycationic region (residues
21–45) of P bind in the vicinity to GAF A as determined by
cross-linking studies (16). In particular, Met-138 and Gly-139
of bovine rod PDE6A were found to cross-link to the polyca-
tionic region (34) (residues correspond to Ile-140 and Gly-141
of chicken PDE6C). Mutations of Val-130 and His-158 (resi-
dues correspond to Val-135 and His-163 of chicken PDE6C)
considerably impaired the interaction with P (33). In the crys-
tal structure of PDE6C, these residues are located within or in
proximity to the highly conserved surface patch (Fig. 3C, left
panel). The abundance of negatively charged residues in this
region is suitable for an ionic interaction with the highly con-
served polycationic region of P. P reportedly prefers the
cGMP-bound state of GAF A (14, 46), but none of the residues
within the surface patch are in close proximity to the binding
pocket suggesting that themechanism of positive cooperativity
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of cGMP and P binding likely involves conformational rear-
rangements of secondary structure elements. Alternatively, the
conserved surfacemay be involved in other intra- and intermo-
lecular interactions.
Concluding Remarks—The crystal structure of PDE6C GAF
A confirms in atomic detail that GAF A is the cGMP-binding
site of PDE6. The structural data in this study and the observed
large conformational change provide important clues to the
molecular basis of cGMP binding and allosteric regulation of
the PDE6 enzyme. The atomic details of its crystal structure,
the small size of the isolated GAF domain, and the large scale
recombinant expression and purification (with and without
cGMP)make PDE6CGAF A amenable to study the interaction
of PDE6 with P and other binding partners.
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